Followers | 27 |
Posts | 5124 |
Boards Moderated | 0 |
Alias Born | 01/27/2014 |
Thursday, February 04, 2016 9:47:15 AM
WEST HARRISON, NY / ACCESSWIRE / February 4, 2016 / A comeback management team has transformed CEL-SCI Corporation (NYSE MKT :CVM) into a classic special situation. That definition is a stock whose price should rise regardless of the overall stock market direction because of its intrinsic value and momentum.
During a recent presentation CEL-SCI CEO Geert Kersten quipped, "Among a class of college students in Economics 101 no one would ever believe the kind of stuff that happens to biotech companies. No one would ever invest if they knew, right? But the flip side is that no where can you make as much money as in small biotech companies which become successful!"
"Sheer persistence," is Kersten's explanation of CEL-SCI's almost miraculously survival. "My management team has been with me for 20 years. Where do you still find that? What holds us together is our data-driven belief that our Multikine drug treatment works."
After significant setbacks, CEL-SCI is approaching the finish line for its world's largest head and neck cancer immunotherapy Phase III study. Almost 700 patients are enrolled at 84 sites in 24 countries including in the U.S., Canada, Israel and parts of Europe and Asia. However, CEL-SCI's recent market cap of $62 million is a tiny fraction of the billions of some earlier stage Phase I or Phase II rivals. Last month to demonstrate his belief things are going well at last , the CEO made his biggest single personal purchase of 3 million shares valued about $1.1 million.
CEL-SCI's unique Phase III study is pioneering injecting its Multikine drug regime for three weeks into the four week window before traditional surgery, radiation and/or chemotherapy. In contrast, other cancer immunotherapy companies, which require much longer treatment times, must aim to boost the immune system after the tumor has recurred. Unfortunately that is also when the immune system may have been debilitated by the toxicity from the earlier surgery, radiation and chemotherapy.
Full enrollment of its trial 880 patients is expected in 2016 with possible study completion in late 2017. If a 10% improvement in patient survival versus the current standard of head and neck cancer care is achieved, CEL-SCI expects to submit a Biologics License Application to the FDA seeking approval of its Multikine drug regime. Success would offer the potential to become the fourth standard of care for head and neck cancer, preceding and joining surgery, chemotherapy and radiation. That would involve about 6% of the world's solid cancers.
Recent CVM News
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors • Business Wire • 04/23/2024 01:00:00 PM
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology • Business Wire • 03/19/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/07/2024 04:33:42 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 04:33:13 PM
- CEL-SCI Corporation Issues Letter to Shareholders • Business Wire • 03/06/2024 01:45:00 PM
- CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results • Business Wire • 02/15/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:31:12 PM
- CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/13/2024 05:00:00 PM
- CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/09/2024 01:30:00 PM
- CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug • Business Wire • 02/06/2024 02:00:00 PM
- European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® • Business Wire • 01/31/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:06:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:00:11 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/22/2023 09:01:06 PM
- CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments • Business Wire • 12/22/2023 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/21/2023 09:15:39 PM
- UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer • Business Wire • 12/04/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 10:25:18 PM
- CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock • Business Wire • 11/20/2023 09:15:00 PM
- CEL-SCI Announces Pricing of $5 Million Offering of Common Stock • Business Wire • 11/16/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 09:01:26 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM